Zhao Chengquan, Elishaev Esther, Yuan Ke-Hai, Yu Jing, Austin R Marshall
Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Cancer. 2007 Oct 25;111(5):292-7. doi: 10.1002/cncr.22949.
The prevalence of high-risk Human Papillomavirus DNA (hrHPV DNA) in women with negative Papanicolaou (Pap) test results provides a measure of residual risk for cervical neoplasia after cytology screening. The purpose of this study was to document the prevalence of hrHPV DNA in several thousand women ages > or =30 years with negative ThinPrep Imaging System (TIS)-imaged Pap test results in a large academic hospital cytology laboratory.
All cytology-negative TIS-imaged ThinPrep Pap tests (TPPT) with hrHPV DNA tests that were performed by the United States Food and Drug Administration (FDA)-approved Hybrid Capture 2 (HC2) method from May 1, 2005 to November 20, 2006 were identified and reviewed. Imaged-negative Pap test slides associated with a positive hrHPV DNA test result were rescreened manually. Variation in hrHPV DNA prevalence was assessed for different age and ethnic groups.
Of 8070 imaged cytology-negative TPPT from women ages 11 to 90 years, hrHPV DNA test results were also available. Among 7426 women ages > or =30 years with a cytology-negative, TIS-imaged, Pap test, a significant age-associated decline in hrHPV DNA prevalence was noted, 3.4% in 3050 women ages 30-45 years, 2.4% in 7426 women ages 30-90 years, and 1.8% in 5491 women ages 40-90 years. The hrHPV DNA-positive rate was 2.3% in 6012 imaged cytology-negative white women and 4.1% in 739 imaged cytology-negative black women.
Very low HC2 hrHPV DNA rates in 7426 women ages > or =30 years with cytology-negative, TIS-imaged, ThinPrep, Pap tests were similar to recently published data from 1 other academic center and lower than rates reported in previous studies on cytology-negative North American or European women screened manually with conventional or liquid-based Pap tests. These data may impact assessments of how best to combine cytology and HPV testing.
巴氏试验（Pap）结果为阴性的女性中高危型人乳头瘤病毒DNA（hrHPV DNA）的流行率可衡量细胞学筛查后宫颈肿瘤形成的残余风险。本研究旨在记录在一家大型学术医院细胞学实验室中，数千名年龄≥30岁、ThinPrep影像系统（TIS）成像的巴氏试验结果为阴性的女性中hrHPV DNA的流行率。
确定并回顾了2005年5月1日至2006年11月20日期间，采用美国食品药品监督管理局（FDA）批准的杂交捕获2代（HC2）方法进行hrHPV DNA检测且细胞学结果为阴性的TIS成像的ThinPrep巴氏试验（TPPT）。对与hrHPV DNA检测结果阳性相关的影像阴性巴氏试验玻片进行人工重新筛查。评估不同年龄和种族组中hrHPV DNA流行率的差异。
在8070例年龄11至90岁的影像细胞学阴性TPPT中，也有hrHPV DNA检测结果。在7426例年龄≥30岁、细胞学阴性、TIS成像的巴氏试验女性中，注意到hrHPV DNA流行率存在与年龄相关的显著下降，3050例30至45岁女性中为3.4%，7426例30至90岁女性中为2.4%，5491例40至90岁女性中为1.8%。6012例影像细胞学阴性的白人女性中hrHPV DNA阳性率为2.3%，739例影像细胞学阴性的黑人女性中为4.1%。
7426例年龄≥30岁、细胞学阴性、TIS成像、ThinPrep巴氏试验的女性中，HC2 hrHPV DNA率极低，与另一个学术中心最近发表的数据相似，且低于先前关于北美或欧洲细胞学阴性女性采用传统或液基巴氏试验人工筛查的研究报告率。这些数据可能会影响对如何最佳结合细胞学和HPV检测的评估。
